Moderna Inc. ($MRNA) Stock Forecast: Down 5.0% Today

What is Moderna Inc.?

Moderna (MRNA) is a pharmaceutical company known for its mRNA vaccine developed during the recent pandemic. The company is now broadening its focus to encompass respiratory and cancer therapies in its product portfolio.

Why is Moderna Inc. going down?

MRNA stock is down 5.0% on Jan 15, 2026 15:16

• Moderna's stocks saw a downward trend today, potentially as investors took profits after a 17% jump post the positive initial financial results for 2025.
• There are concerns among analysts and investors regarding Moderna's shift away from solely focusing on COVID-19 vaccines to a more extensive pharmaceutical range, particularly in light of upcoming critical events like the Phase 3 cancer vaccine trial outcome and patent dispute.
• The recent downgrade of Absci Corporation (ABSI) by a financial institution could have impacted the market sentiment surrounding biotech firms like Moderna, underscoring the sector's inherent risks.
• Despite the recent decline in stock value, Moderna's strategic evolution and ongoing progress in its pipeline projects suggest that it could maintain a significant position in the pharmaceutical landscape over the long haul.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

Moderna (Nasdaq: MRNA) is undergoing a critical transformation in early 2026, pivoting from a COVID-19 vaccine-centric company to a diversified pharmaceutical player with a focus on a multi-product "respiratory franchise" and individualized cancer therapy. After a significant decline from its pandemic-era peak, the company is working to achieve cash flow breakeven by 2028, balancing high R&D spending with a crucial cost-reduction program. Key events for 2026 include a high-stakes patent trial in March and the anticipated top-line results for its Phase 3 cancer vaccine trial in late autumn, which will heavily influence its future valuation and market position.

https://markets.financialcontent.com/stocks/article/finterra-2026-1-14-modernas-high-stakes-transformation-navigating-the-post-pandemic-pivot

Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials

Morgan Stanley downgraded Absci Corporation (ABSI) to Equalweight and cut its price target to $4.32 from $5.80 due to increased risk and limited near-term visibility. This follows interim Phase 1 data for ABS-101 falling short of expectations, leading Absci to shift focus to ABS-201, a program for androgenetic alopecia. Analysts caution about execution risk given the early stage of ABS-201 and Absci's less established competitive position in dermatology.

https://finviz.com/news/276617/analysts-cut-absci-absi-target-spotlight-new-alopecia-therapy-in-early-trials

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

Moderna, Inc. is undergoing a significant transformation in early 2026, aiming to diversify beyond its COVID-19 vaccine success into a multi-product respiratory franchise and individualized cancer therapies. The company faces challenges including declining COVID-19 revenues, intellectual property litigation, and high R&D costs, with a crucial Phase 3 cancer data readout and a patent trial expected in late 2026. Despite a current "Hold" rating from analysts, success in its oncology pipeline could reposition Moderna as a leader in personalized medicine.

https://markets.financialcontent.com/wral/article/finterra-2026-1-14-modernas-high-stakes-transformation-navigating-the-post-pandemic-pivot

Moderna 2026 at JPM 2026: Projects $1.9B Revenue and Eyes Vaccine Approvals

Moderna forecasts up to 10% revenue growth in 2026, expecting approximately $1.9 billion in revenue, exceeding previous guidance. The company anticipates pivotal clinical data across its oncology, rare disease, and infectious disease programs, with potential approvals for seasonal influenza and combined flu/COVID vaccines next year. Moderna also reported strong 2025 performance, including a reduction in operating expenses by about $2 billion and year-end cash and investments reaching approximately $8.1 billion.

https://www.geneonline.com/moderna-2026-at-jpm-2026-projects-1-9b-revenue-and-eyes-vaccine-approvals/

Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results

Moderna (MRNA) saw its stock rocket by 17.02% after releasing strong preliminary financial results for full-year 2025. The company expects revenues of $1.9 billion for 2025, exceeding its previous guidance, and projects up to 10% revenue growth for 2026 while aiming for break-even in 2028 by reducing operating expenses. CEO Stephane Bancel highlighted strengthened commercial execution and advancements in their mRNA pipeline, particularly focusing on seasonal vaccines, oncology, and rare disease innovations.

https://finance.yahoo.com/news/moderna-mrna-rockets-17-strong-120905192.html

Trending Today

Goldman Sachs Group Inc. (The) ($GS) Stock Forecast: Up 5.2% Today

Alaska Air Group Inc. ($ALK) Stock Forecast: Up 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Up 2.8% Today

BlackRock Inc. ($BLK) Stock Forecast: Up 6.1% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.3% Today

fuboTV Inc. ($FUBO) Stock Forecast: Up 6.4% Today

Astera Labs Inc ($ALAB) Stock Forecast: Up 5.4% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Up 5.1% Today

Citigroup Inc. ($C) Stock Forecast: Up 5.2% Today

Unity Software ($U) Stock Forecast: Up 5.3% Today

Moderna Inc. Price History

13.00.2026 - MRNA Stock was up 17.4%

• Moderna's stock saw a notable 12% increase following the release of its optimistic 2025 financial forecasts, reflecting strong investor trust in the company's potential for future growth.
• The company's strategic pivot towards infectious diseases, oncology, and rare diseases, combined with operational cost reductions and advancements in its pipeline, have reinforced Moderna's long-term prospects and supported the positive market response.
• Encouraging announcements made at the J.P. Morgan Healthcare Conference, such as anticipated revenue growth in 2026 and progress in late-stage pipeline developments, have further bolstered investor confidence and contributed to the stock's upward trajectory.
• Moderna's recent market success stems from a blend of promising financial forecasts, strategic focus on key therapeutic areas, and favorable updates on its pipeline and business outlook.

13.00.2026 - MRNA Stock was up 16.6%

• Following various favorable developments, Moderna's stock witnessed a significant bullish surge:
• The unveiling of its 2025 financial forecasts displaying promising growth potential led to a 12% increase in stock value.
• Optimistic news regarding its business and pipeline at the J.P. Morgan Healthcare Conference heightened investor confidence.
• Analyst upgrades and company initiatives strengthened investor belief in Moderna's future performance.
• Technical analysis indicates a potential upward trend for Moderna's stock, suggesting a breakout after a period of underwhelming performance.
• Moderna's strategic pivot towards infectious disease, oncology, and rare diseases, coupled with key catalysts like Intismeran/Keytruda Phase II and III readouts, has attracted long-term investors despite near-term revenue setbacks, presenting a high-risk recovery narrative.
• Overall, a series of positive developments, robust financial projections, and strategic moves have driven Moderna's stock price up, signaling an optimistic outlook for the company in the near term.

31.11.2025 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement, closing down 2.38% in the recent trading session, underperforming the broader market indices.
• The significant layoffs in the biotech industry, including at Moderna, may have contributed to investor concerns about the company's future growth prospects.
• Despite the recent dip, Moderna has shown strong performance over the past month, outpacing the Medical sector, indicating potential volatility in response to market news and events.
• The upcoming Investor Event – Analyst Day hosted by Moderna could provide insights into the company's strategic direction, potentially impacting investor sentiment and stock movement in the near future.

08.00.2026 - MRNA Stock was down 5.3%

• Moderna experienced a bearish trend today, possibly due to investors taking profits following a recent surge in the stock price.
• The positive updates on Moderna's enhanced COVID-19 vaccine combating the LP.8.1 variant may have been factored into the stock price, prompting a sell-off after the announcement.
• Investor caution could be influenced by potential competition and legal issues affecting other biotech firms like BioNTech, which could impact Moderna's market standing and revenue in the future.
• While Moderna continues to make significant progress in vaccine development, short-term stock movements can be influenced by market dynamics and external factors.

15.00.2026 - MRNA Stock was down 5.0%

• Moderna's stocks saw a downward trend today, potentially as investors took profits after a 17% jump post the positive initial financial results for 2025.
• There are concerns among analysts and investors regarding Moderna's shift away from solely focusing on COVID-19 vaccines to a more extensive pharmaceutical range, particularly in light of upcoming critical events like the Phase 3 cancer vaccine trial outcome and patent dispute.
• The recent downgrade of Absci Corporation (ABSI) by a financial institution could have impacted the market sentiment surrounding biotech firms like Moderna, underscoring the sector's inherent risks.
• Despite the recent decline in stock value, Moderna's strategic evolution and ongoing progress in its pipeline projects suggest that it could maintain a significant position in the pharmaceutical landscape over the long haul.

14.00.2026 - MRNA Stock was up 13.7%

• Moderna's stock saw a significant increase today due to an optimistic revenue outlook for 2026, anticipating up to $1.9 billion in revenue and potential vaccine approvals.
• Moderna's positive performance contrasts with the challenges faced by Apellis Pharmaceuticals, whose stock prices have declined despite positive revenue updates, reflecting market sentiment discrepancies.
• The recent acquisition offer by BioNTech for CureVac has brought stability to CureVac's stock, underscoring the significance of strategic partnerships in the biotech field.
• The upbeat movement in Moderna's stock might also be influenced by the growing focus on vaccine manufacturers like Novavax, as the CDC notes a surge in respiratory ailments, creating a favorable landscape for vaccine-related companies.

14.00.2026 - MRNA Stock was up 6.2%

• Moderna's stock saw a significant 17% increase after announcing strong preliminary financial results for full-year 2025, surpassing revenue expectations and predicting growth for 2026.
• Investor confidence in Moderna's future prospects grew as the market reacted positively to the company's shift towards a multi-product respiratory franchise and personalized cancer treatments.
• The bullish trend was influenced by expectations surrounding upcoming events like the Phase 3 cancer vaccine trial results and a patent trial in late 2026, with potential implications for Moderna's market position and valuation.
• Moderna's strategies to lower operating costs, achieve cash flow breakeven by 2028, and advance its pipeline, notably in seasonal vaccines, oncology, and rare diseases, further bolstered investor optimism and drove up the stock price.

06.00.2026 - MRNA Stock was up 6.0%

• Moderna's stock observed a positive uptrend today due to encouraging updates on the company's vaccine progress and submissions for its seasonal influenza vaccine candidates.
• The recent funding from CEPI for a crucial Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine reflects a strong vote of confidence in the company's technology and its potential role in global pandemic readiness.
• Regulatory filings for Moderna's mRNA-1010 seasonal influenza vaccine in significant markets like the U.S., EU, Canada, and Australia, supported by favorable Phase 3 trial results, have boosted investor confidence in the company's future growth prospects.
• Moderna's confirmed revenue outlook and forthcoming milestones, including the launch of multiple vaccines post-COVID-19, signal a solid long-term strategy that has resonated well with investors, underpinning the optimistic market sentiment towards the stock.

06.00.2026 - MRNA Stock was up 11.9%

• The rise in Moderna's stock today is linked to encouraging developments related to the company's vaccine technology:
• Funding from CEPI for a pivotal Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine candidate indicates strong belief in the company's technology and its potential for global pandemic preparedness.
• Regulatory submissions for Moderna's seasonal influenza vaccine, mRNA-1010, in various countries, backed by favorable Phase 3 study results, underscore the company's dedication to broadening its vaccine range and addressing public health requirements.
• Moderna's focus on using mRNA technology to better align with changing flu strains and its dedication to keeping vaccine prices reasonable and ensuring equal access for lowto middle-income nations further increases investor confidence in the company's growth prospects.
• Positive clinical trial outcomes, advancements in regulatory processes, and strategic moves in vaccine creation collectively position Moderna as a significant player in the healthcare industry, boosting investor confidence and contributing to today's bullish market activity.

06.00.2026 - MRNA Stock was up 11.5%

• Moderna's stock price saw a significant upsurge today following the company's submission of regulatory filings for its seasonal influenza vaccine, mRNA-1010, in multiple countries. This announcement has sparked investor confidence in the expansion of Moderna's non-COVID product range and the growth potential of its flu vaccine.
• The rise in Moderna's stock price was also supported by BofA Global Research raising its price target for the company, indicating strong belief in its new product releases and future opportunities.
• Despite analysts maintaining a "Reduce" consensus rating on Moderna due to concerns about revenue decline and profitability, the positive updates on the flu vaccine submissions and cost-saving measures have overshadowed these reservations, propelling the stock's bullish performance today.
• A global market analysis forecast predicting substantial growth in the mRNA cancer vaccine biologic lines market has likely bolstered the optimistic sentiment surrounding Moderna, underlining its potential for further expansion and revenue generation in the biotech industry.

24.11.2025 - MRNA Stock was down 5.7%

• Moderna’s stock saw a decline to approximately $32.29 after a surge in late December. Several factors contributed to this movement:
• Investor worries regarding bird flu funding from CEPI and the progress of Moderna's mNEXSPIKE vaccine evaluated by the European Medicines Agency.
• Scrutiny on the company's financial moves, which include securing a $1.5 billion loan and outlining 2026 growth targets.
• Analysts have an overall "Hold" consensus rating with an average 12-month target price of $33.25, reflecting a cautious stance on the stock.
• The recent uptick in Moderna’s stock was primarily due to enhanced liquidity and cost containment rather than fundamental business growth, leading some investors to sell and reap profits. The decision aligns with concerns about declining fundamentals, like terminating the CMV program, which could impact the company's future prospects and pipeline.
• Today's bearish movement in Moderna’s stock seems to stem from profit-taking post a recent rally, investor focus on key developments and funding, and uncertainties about the company’s strategic path amidst evolving market trends.

13.00.2026 - MRNA Stock was up 7.7%

• Moderna's positive momentum today is linked to updates shared at the 44th Annual J.P. Morgan Healthcare Conference. Notably, the company revealed optimistic revenue growth forecasts for 2026 and progress in advancing its late-stage pipeline.
• Investor confidence in Moderna was likely bolstered by expectations of potential product approvals for flu and flu/COVID combinations in 2026, alongside upcoming pivotal trial data releases in various therapeutic areas.
• The appointment of Moderna's CEO, Stephane Bancel, to the Board of Directors of Commonwealth Fusion Systems is seen as a positive move that highlights Bancel's expertise and the potential synergies between the two companies.
• The company's strategic focus on key therapeutic areas, coupled with the encouraging outlook presented at the conference, has generated optimism among investors and propelled Moderna's stock performance.